11/20
01:16 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
10/11
03:42 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
9/26
10:15 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.
9/26
10:15 am
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $42.00 price target on the stock.
9/26
10:06 am
arwr
Rating for ARWR
Low
Report
Rating for ARWR
9/26
10:06 am
arwr
Rating for ARWR
Low
Report
Rating for ARWR
9/9
01:03 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/9
12:55 pm
arwr
Rating for ARWR
Low
Report
Rating for ARWR
9/3
02:08 pm
arwr
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.